LumaCyte, Inc. applications

Laser Force Cytology™ (LFC), rapid viral infectivity assay data correlates tightly with traditional plaque and TCID50 assays. Radiance® provides new information around host response and the viral life cycle, enabling a better understanding of cellular infection through the measurement of novel phenotypic changes.

Real-time Viral Titer Assay Capability. Current viral titer assay methods, a crucial component of vaccine & CGT development and production efforts, are generally slow, labor intensive, subjective, and difficult to standardize, often resulting in large errors or failures during critical production timepoints.

Laser Force Cytology (LFC) and Radiance label-free approach to cell therapy research and biomanufacturing has significant value in expediting the process, decreasing costs, and ensuring therapy effectiveness and quality. Radiance enhances the highly complex biomanufacturing process for cell therapies by providing new insights to cell therapy research and process development. Current process development assays are fraught with difficult and time-consuming steps requiring highly skilled scientists and bioengineers to produce these life saving treatments and cures.